Tarsus Pharmaceuticals Inc. (TARS) Fundamentals

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
SHARE INFORMATION
Market Cap$ 451,513,984
Shares Outstanding26,327,346
Float19,417,077
Percent Float73.75%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 57,027,000
Latest Fiscal EPS$ -0.72
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions129
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months828,962
Institutional Holdings Percent57.9%
Institutional Sold Previous 3 Months1,656,963
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months177,257
Insider Holdings Percent5.8
Insider Sold Previous 3 Months522,587
Insider Shares Owned1,517,038
TRADING INFO
52 Week High$ 31.00
52 Week Low$ 10.80
52 Week High Change$ -28.21
21 Day Moving Average$ 15.2262
21 Day Extended Moving Average$ 15.4233
50 Day Moving Average$ 14.569
50 Day Extended Moving Average$ 15.0837
200 Day Moving Average$ 19.0638
200 Day Extended Moving Average$ 18.7532
10 Day Average Volume75,302
20 Day Average Volume71,560
30 Day Average Volume130,405
50 Day Average Volume162,782
Alpha-0.009164
Beta1.0242
Standard Deviation0.213384
R20.062251
7 Day Price Change$ 2.08
7 Day Percent Change13.8%
21 Day Price Change$ 2.62
21 Day Percent Change18.03%
30 Day Price Change$ 2.12
30 Day Percent Change14.11%
Month to Date Price Change$ 2.13
Month to Date Percent Change14.18%
Quarter to Date Price Change$ 2.55
Quarter to Date Percent Change17.47%
180 Day Price Change$ -0.40
180 Day Percent Change-2.28%
200 Day Price Change$ -3.60
200 Day Percent Change-17.35%
Year to Date Price Change$ -5.35
Year to Date Percent Change-23.78%

Tarsus Pharmaceuticals Inc. (TARS) Key Ratios

PROFITABILITY
EBIT Margin-175.7%
EBITDA Margin-174.5%
Pre-Tax Profit Margin0.0%
Profit Margin Count-24.25%
Gross Margin96.6%
Profit Margin TOT-24.25%
INCOME STATEMENTS
Revenue$ 2,117,000
Revenue Per Share$ 0.0804
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book3.00
Total Debt To Equity0.10
Int Coverage0.00
Current Ratio14.20
Leverage Ratio1.10
Quick Ratio13.90
Long Term Debt To Capital0.12
VALUATION MEASURES
PE Ratio-7.90
Enterprise Value$ 297,680,077
Price to Sales213.2801
Price to Free Cash-21.70
PE High Last 5 Years0.00
Price To Book3.00
Price To Cash Flow1,386.50
PE Low Last 5 Years0.00
Price to Tangible Book3.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.10
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-23.63
Return on Equity-26.68
Return on Capital-25.09

Tarsus Pharmaceuticals Inc. (TARS) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorErnst & Young LLP
CEOBobak Azamian
Emplyoees46
Last AuditUQ
CIK0001819790
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address15440 Laguna Canyon Road
Suite 160
Irvine, CA 92618
Websitehttps://www.tarsusrx.com
Facsimile-
Telephone+1 949 409-9820
Emailinfo@tarsusrx.com


Your Recent History
NASDAQ
TARS
Tarsus Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.